WIN-CONSORTIUM
17.5.2019 11:40:10 CEST | Business Wire | Press release
The 11th WIN Symposium in Precision Oncology will be held in Paris, France on June 23-24, 2019.
ASCO® endorsed for the past 11 years, the WIN symposium will deliver an
exciting line-up of speakers in Paris (France) on June 23-24, 2019 to
discuss Innovation and Global Deployment of Precision Oncology.
The
current status of Precision Oncology across the globe will be examined
with the exceptional participation of the chairmen of the event, Richard
L. Schilsky, Chairman WIN Consortium(*)
, Senior
Vice-President and Chief Medical Officer of ASCO, and Josep Tabernero,
Vice Chairman WIN Consortium, President of ESMO and Director of Vall
d’Hebron Institute of Oncology, Spain.
Global experience will be shared:
- Optimizing Patient Enrollment and Efficacy of Precision Oncology Clinical Trials at UT MD Anderson Cancer Center, USA
- Decision Support for Precision Oncology: Evolving from Monotherapy to Genomically Informed Combinations, UT MD Anderson Cancer Center, USA
- The Value of Personalized Medicines for Healthcare Systems in Europe – by the European Biopharmaceutical Enterprises (EBE) and the European Federation of Pharmaceutical Industries and Associations (EFPIA)
- Rapidly changing landscape of Precision Medicine in Japan, Tokyo Medical and Dental University
- National Cancer Grid of India – Earthshots over Moonshots, TATA Memorial Hospital
- Development and Application of Precision Oncology in China, Fudan University Shanghai Cancer Center
World leading precision oncologists will deliver breakthrough science, including:
- Prof. Jennifer A. Doudna, PhD, University of California, Berkeley, USA “Rewriting the Code of Life: CRISPR-Cas Genome Editing”.
- Dr. Jennifer A. Ligibel, MD, Harvard Medical School and Dana Farber Cancer Institute, USA “Lifestyle-based Prevention Strategies”.
- Dr. Razelle Kurzrock, MD, University of California, San Diego, USA, “Innovation in Clinical Trials: WINTHER trial”, first study pioneered by the WIN Consortium (*) , that showed that assessing RNA is an important adjunct to DNA profiling for determining treatments and rings in a new era for personalized medicine in oncology. WINTHER results were recently published in Nature Medicine (**)
- Prof. Christophe Le Tourneau, MD., PhD, Institut Curie, France, “Innovative Ways of Assessing Durable Response under Immunotherapy”
- Dr. Jean François Martini, PhD., MSc, Pfizer Inc., “Addressing Mechanisms of Resistance Following Anti-Cancer Therapy: a Pharma Perspective”
- Prof. Angel Porgador, PhD, Ben Gurion University of Negev, Israel, “Efficient In Vitro Screening for Drug Combinations: The TEVA Model”
Do not miss the two microsatellites hosted at the WIN Symposium:
- Real-World Evidence and its Relevance for Clinical Practice and Stakeholder Decision Making - F. Hoffmann-La Roche Ltd
- Artificial Intelligence to Support Patient Profiling in Precision Oncology - Definiens AG
The WIN symposium provides outstanding networking opportunities for all professionals in cancer care.
(*) WIN Consortium is a non-profit organization based in Paris, France. We are a worldwide network assembling cancer stakeholders from four continents to develop cutting edge concepts and clinical trials that improve survival for cancer patients. WIN members include 28 outstanding cancer centers plus 11 additional leading pharmaceutical, technology companies and patient advocacy organizations representing stakeholders in precision cancer medicine, www.winconsortium.org
(**) Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial https://doi.org/10.1038/s41591-019-0424-4
For more information: www.winsymposium.org
ASCO® is a registered trademark of the American Society of Clinical Oncology®. Used with permission. This is not an ASCO sponsored event.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190517005150/en/
Contact:
WIN Consortium Vladimir Lazar Chief Scientific and Operating Officer vladimir.lazar@winconsortium.org Telephone: + 33 66 109 15 22
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Intuit Mailchimp Unlocks a New Era of Profitable Ecommerce Marketing with Advanced, Data-Driven Capabilities10.2.2026 14:30:00 CET | Press release
Built to deliver ROI for less cost, Mailchimp now combines unified data with powerful automation across email and messagingProduct innovations available in 185 countries and territories across North America, Latin America, EMEA and APACSMS launching in 34 new markets across EMEA including Belgium, Sweden, Denmark, Norway, Finland, Portugal, Greece, Poland and more Intuit Inc. (Nasdaq: INTU), the global financial technology platform that makes Intuit TurboTax, Credit Karma, QuickBooks, and Mailchimp, today announced a set of Mailchimp product innovations that unlock profitable growth for ecommerce businesses. Powered by the Intuit platform, the enhancements include more ways for merchants to connect their data and activate omnichannel campaigns driving up to 30x ROI for ecommerce customers1 without the added price or complexity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210726144/en/ Built to deliver ROI for less cost
ILiAD Biotechnologies Announces $115M Oversubscribed Series B Financing to Advance BPZE1 Pertussis Vaccine10.2.2026 14:00:00 CET | Press release
Financing round led by RA Capital ManagementProceeds to support Phase 3 development of BPZE1 with pivotal study to begin in 2026 ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the successful closing of an oversubscribed $115 million Series B financing. The financing was led by RA Capital Management with participation from new investors Janus Henderson Investors and BNP Paribas Asset Management Alts, as well as existing investors including a multi-national pharmaceutical company and AI Life Sciences. As part of the financing, Mario Barro, Ph.D., Head of Infectious Diseases at RA Capital Management has joined ILiAD’s Board of Directors. Proceeds from the Series B financing will support the advancement of ILiAD’s next generation pertussis vaccine candidate, BPZE1. Inducing both systemic and mucosal immunity, BPZE1 is a live attenuated intranasal pertussis vac
Armis Launches Armis Centrix™for Application Security to Secure the Code that Runs Organizations10.2.2026 14:00:00 CET | Press release
Solution helps security teams reduce cyber risk exposure, operate more efficiently and streamline their security stack Armis, the cyber exposure management & security company, today announced Armis CentrixTM for Application Security, which unifies application security across an organization’s software development lifecycle. The technology helps security teams secure code as a next-generation attack vector to fortify organizations’ defenses and protect against cyber threats. “To effectively manage risk, it’s essential to get to the root cause of the problem and weed it out,” said Nadir Izrael, CTO and Co-Founder of Armis. “Code-based vulnerabilities are being embedded into organizational infrastructure, and AI-generated code is exacerbating the problem, containing exponentially more vulnerabilities when compared to code written by human developers. As enterprises embrace AI-assisted coding and drive continuous development pipelines, they need a smarter, more dynamic, and unified approac
Sam Elbeck of ExaGrid Honored as a 2026 CRN® Channel Chief10.2.2026 14:00:00 CET | Press release
ExaGrid®, the industry’s only Tiered Backup Storage solution with AI-Powered Retention Time-Lock (RTL) that includes a non-network-facing tier (creating a tiered air gap), delayed deletes and immutability for ransomware recovery,today announced that CRN®—a brand of The Channel Company—has selected Sam Elbeck, ExaGrid’s Vice President of Americas Sales and Channel Partners, for inclusion on the prestigious 2026 CRN® Channel Chiefs list. This annual recognition celebrates IT vendor and distribution executives who are shaping channel strategy and driving innovation and partnership across the industry. “It’s an honor to be named to the Channel Chiefs list again this year,” said Sam Elbeck. “We are committed to the channel and view our partners as an extension of ExaGrid. We collaborate closely on every opportunity to ensure mutual success. Our channel philosophy centers on building long-term relationships grounded in honesty, integrity, and transparency. We strive for ExaGrid to be known a
Vasion Appoints Scott Lee as Chief Product Officer to Accelerate the Impact of Intelligent Print Automation10.2.2026 14:00:00 CET | Press release
Seasoned enterprise product leader brings proven track record of scaling product organizations and driving exponential value Vasion, a leader in serverless printing and Intelligent Print Automation, today announced the appointment of Scott Lee as Chief Product Officer. Lee brings more than 25 years of C-level product and growth leadership experience transforming and scaling enterprise SaaS companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210803525/en/ Scott Lee joins Vasion as Chief Product Officer, bringing more than 25 years of enterprise SaaS leadership experience to accelerate the company's intelligent print automation platform and AI-ready capabilities. As Chief Product Officer at Vasion, Lee will lead product management, product design, and product operations. He will focus on expanding strong product foundations and ensuring customer value as the company scales. His extensive experience modernizing complex
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom